Literature DB >> 29016451

CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.

Alexandre Matet1, Suzanne Yzer2, Emily Y Chew3, Alejandra Daruich1, Francine Behar-Cohen4,5, Richard F Spaide6,7.   

Abstract

PURPOSE: To describe cases presenting with features of idiopathic macular telangiectasia (MacTel) Type 2 and central serous chorioretinopathy (CSC).
METHODS: Databases from four tertiary retina centers were searched for cases copresenting CSC and MacTel Type 2.
RESULTS: Five cases were identified (4 men, 1 woman; mean age: 67.2 years). Four patients were referred for chronic or nonresolving CSC, and the diagnosis of MacTel Type 2 was made based on multimodal imaging findings. One patient had advanced MacTel Type 2, and developed acute CSC. Regarding the MacTel Type 2 findings, all subjects presented perifoveal telangiectasia on fluorescein angiography, and four subjects showed intraretinal cavitations typical of MacTel Type 2 on optical coherence tomography, in one or both eyes. Regarding the CSC findings, fluorescein angiography identified focal or extended retinal pigment epithelium alteration in all eyes, and an active leakage in two eyes. Indocyanine green angiography showed choroidal vascular hyperpermeability in four subjects. On optical coherence tomography, pigment epithelial detachments were detected in five eyes (four subjects), and foveal detachments were present in five eyes (three subjects), which spontaneously resolved (two eyes), responded to photodynamic therapy (two eyes), or persisted (one eye). Mean choroidal thickness was 402 ± 99 μm.
CONCLUSION: The codiagnosis of CSC and MacTel Type 2 should be considered in atypical presentations associating features from both disorders.

Entities:  

Mesh:

Year:  2018        PMID: 29016451      PMCID: PMC5726910          DOI: 10.1097/IAE.0000000000001836

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  66 in total

1.  How prevalent is macular telangiectasia type 2?

Authors:  Emily Y Chew
Journal:  Ophthalmic Epidemiol       Date:  2012-02-24       Impact factor: 1.648

2.  Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2.

Authors:  Hemal Mehta; Simone Müller; Catherine A Egan; Simona Degli Esposti; Adnan Tufail; Dawn A Sim; Frank G Holz; Andrew C Browning; Winfried M Amoaku; Peter Charbel Issa; Mark C Gillies
Journal:  Br J Ophthalmol       Date:  2016-10-28       Impact factor: 4.638

3.  High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy.

Authors:  Sotaro Ooto; Masanori Hangai; Kohei Takayama; Naoko Arakawa; Akitaka Tsujikawa; Hideki Koizumi; Susumu Oshima; Nagahisa Yoshimura
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-25       Impact factor: 4.799

4.  Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration.

Authors:  Eiko K de Jong; Myrte B Breukink; Rosa L Schellevis; Bjorn Bakker; Jacqueline K Mohr; Sascha Fauser; Jan E E Keunen; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon
Journal:  Ophthalmology       Date:  2014-11-06       Impact factor: 12.079

5.  Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.

Authors:  Raja Narayanan; Jay Chhablani; Manish Sinha; Vivek Dave; Mudit Tyagi; Rajeev R Pappuru; Baruch D Kuppermann
Journal:  Retina       Date:  2012 Nov-Dec       Impact factor: 4.256

Review 6.  Type-A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Retina       Date:  1987       Impact factor: 4.256

7.  Choroidal thickness in macular telangiectasia type 2.

Authors:  Jay Chhablani; Igor Kozak; Ganesh Babu Jonnadula; Amarnath Venkata; Raja Narayanan; Rajeev Reddy Pappuru; Podili Srinivas Rao
Journal:  Retina       Date:  2014-09       Impact factor: 4.256

8.  Medical characteristics of patients with macular telangiectasia type 2 (MacTel Type 2) MacTel project report no. 3.

Authors:  Traci E Clemons; Mark C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Jie Jin Wang; Paul Mitchell; Wishal D Ramdas; Johannes R Vingerling
Journal:  Ophthalmic Epidemiol       Date:  2013-04       Impact factor: 1.648

9.  The relationship between inner retinal cavitation, photoreceptor disruption, and the integrity of the outer limiting membrane in macular telangiectasia type 2.

Authors:  Meidong Zhu; Matthew Krilis; Mark C Gillies
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

10.  Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study.

Authors:  Der-Chong Tsai; Shih-Jen Chen; Chin-Chou Huang; Pesus Chou; Chia-Min Chung; Po-Hsun Huang; Shing-Jong Lin; Jaw-Wen Chen; Tseng-Ji Chen; Hsin-Bang Leu; Wan-Leong Chan
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

View more
  3 in total

1.  Global Connections to Study Idiopathic Macular Telangiectasia Type 2.

Authors:  Emily Y Chew; Martin Friedlander
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

2.  Multicolour imaging signatures to diagnose concurrent macular telangiectasia type 2 and macular branch retinal vein occlusion.

Authors:  Ike Schouten; Sugandha Goel; Kumar Saurabh; Rupak Roy
Journal:  GMS Ophthalmol Cases       Date:  2019-11-20

3.  A Splicing Mutation in Slc4a5 Results in Retinal Detachment and Retinal Pigment Epithelium Dysfunction.

Authors:  Gayle B Collin; Lanying Shi; Minzhong Yu; Nurten Akturk; Jeremy R Charette; Lillian F Hyde; Sonia M Weatherly; Martin F Pera; Jürgen K Naggert; Neal S Peachey; Patsy M Nishina; Mark P Krebs
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.